Email this article 
Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
- Authors: Bessmeltsev S.S.1, Stelmashenko L.V.1, Podoltseva E.I.2, Kariagina E.V.3, Salogub G.N.4, Nisamutdinova А.S.5, Matuhina L.M.6, Abdulkadyrov K.M.1
-
Affiliations:
- Russian Research Institute of Hematology and Transfusiology
- City Hospital 31
- City Hospital 15
- St. Petersburg State Pavlov Medical University
- Alexandrovsky Hospital
- Road Clinic Hospital
- Issue: No 4 (2007)
- Pages: 61-66
- Section: THERAPY OF HEMATOLOGIC MALIGNANCIES
- Published: 23.11.2007
- URL: https://oncohematology.abvpress.ru/ongm/article/view/676
- DOI: https://doi.org/10.17650/1818-8346-2007-0-4-61-66
- ID: 676
Cite item
Full Text
Abstract
Theproteasome inhibitor bortezomib (Velcade) has demonstrated clinical activity in patients with multiple myeloma (MM). We report the activity of borte-zomib plus dexamethasone in 60patients with relapsed and refractory myeloma. The patients had a median age of 65 years (range, 38—79 years). The median number of previous treatments was 3 (range, 1-9). For patients who received bortezomib plus dexamethasone the overall response rate was 73%. 38% patients achieved CR. CR in patients receiving bortezomib plus dexamethasone earlier vs later (≤ 3 и ≥ 4 line chemotherapy) were: 48% vs 27,5%. Bortezomib is active in patients with relapsed MM, including elderly patients. Side effects were predictable and manageable; principal toxicities were hematological, gastrointestinal, and peripheral neuropathy. The most common adverse events reported were asthenia (52%), neuropathy (53%), thrombocytopenia (32%), anemia (30%). Neuropathy greater than grade 2 was more frequent in patients who received 3 or more prior therapy regimens.
About the authors
S. S. Bessmeltsev
Russian Research Institute of Hematology and Transfusiology
Author for correspondence.
Russian Federation
L. V. Stelmashenko
Russian Research Institute of Hematology and TransfusiologyRussian Federation
E. I. Podoltseva
City Hospital 31Russian Federation
E. V. Kariagina
City Hospital 15Russian Federation
G. N. Salogub
St. Petersburg State Pavlov Medical UniversityRussian Federation
А. S. Nisamutdinova
Alexandrovsky HospitalRussian Federation
L. M. Matuhina
Road Clinic Hospital
St-Petersburg
Russian FederationK. M. Abdulkadyrov
Russian Research Institute of Hematology and TransfusiologyRussian Federation
References
Supplementary files
